Guggenheim Reiterates Buy Rating on ADC Therapeutics S.A. (ADCT)

Market Context

ADC Therapeutics S.A. operates in the Healthcare sector. The stock currently trades at $1.10 with a market capitalization of $507.9M. The stock has declined 67.3% over the past 52 weeks.

Analyst coverage from Guggenheim provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ADC Therapeutics S.A.

Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.

Recent Analyst Activity for ADC Therapeutics S.A.

Among the 10 most recent ratings: 8 Buy, 2 Hold, 0 Sell.

Date	Firm	Rating	Price Target
Aug 17, 2026	Guggenheim	Buy	N/A
Jun 08, 2026	HC Wainwright & Co.	Neutral	N/A
Jun 04, 2026	RBC Capital	Sector Perform	N/A
May 05, 2026	HC Wainwright & Co.	Buy	N/A
May 05, 2026	RBC Capital	Outperform	N/A

Related Tools: Analyst Ratings Dashboard | View ADCT Stock Page